Patients from group 1 (n~44) will receive the study medication (dapagliflozin) and the ones from Group 2 (n~44) will receive the comparator gliclazide MR on top of usual treatment for type 2 diabetes. Treatments with the study medication or comparator will last 12+/-1 weeks. All patients for both groups will receive the same guidelines about the diet (caloric and macronutrient contents) and physical activity by the same dietitian from the study site at the beginning of study. A "blinded to the patient" Continuous Glucose Monitoring System (CGMS, iPro2 (TM) with Enlite-Sensor (TM); Medtronic Mini-Med Inc., Northridge, California, USA) will be inserted subcutaneously. The sensor is a glucose oxidase-based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall and allows up to 288 glucose readings per day. The CGMS will be placed for 72 hours at beginning (in the last three days of run-in phase) before starting the study medications and again at the end of the study in the last three days of the study treatment. The validated softwares Glyculator (TM) or EasyGV (TM) will calculate the glycemic variability parameters MAGE, SD and CV IQR will be calculated by the software Captür-AGP (TM). Biochemical markers of glycemic control (HbA1c, fasting glucose and postprandial glucose) will be determined at beginning and at the end of the treatment period. Each patient will maintain regular visits to his assistant doctor. At the end, the two groups will be compared according to the following parameters calculated based on results obtained on both CGMS tests, blood samples and patient Clinical Research Form (CRF)